Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Texas Instruments Incorporated — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while Texas Instruments Incorporated trades at $306.01 (market cap $283.46B). The key difference: Texas Instruments Incorporated is far larger — about 7.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Texas Instruments Incorporated pays a 1.82% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TXN | |
|---|---|---|
Market Cap | $39.89B | $283.46B |
Sector | Health | Technology |
52-Week High | $491.22 | $332.35 |
52-Week Low | $278.09 | $153.33 |
Enterprise Value | $38.15B | $292.40B |
Dividend Yield | — | 1.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Texas Instruments (TXN) trades at $311.51, up 0.94% today, showing strong technical momentum with a bullish moving average signal. The company reported mixed Q1 2026 earnings, beating expectations with $1.68 EPS versus $1.36 expected, while Q3 and Q4 2025 missed. Recent CFO transition to Julie Knecht signals stable leadership. Revenue grew to $17.68B in 2025 from $15.6B in 2024, with net income margin at 29.11%.
Outlook remains positive with 65 analysts showing 48% buy rating and $310.95 consensus target. Key risks include high valuation multiples (P/E 53.24) and rising debt-to-asset ratio (40.61% in 2025). AI-driven data center demand presents growth opportunity, but competition and macroeconomic pressures warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
